Eur Rev Med Pharmacol Sci 2018; 22 (18): 5972-5979

DOI: 10.26355/eurrev_201809_15928

MicroRNA-217 alleviates development of non-small cell lung cancer by inhibiting AKT3 via PI3K pathway

Y.-J. Qi, W.-J. Zha, W. Zhang

Department of Respiratory Medicine, Jiangsu Province Hospital of TCM, The Affiliated Hospital of Nanjing University of TCM, Nanjing, China. qwqwwz@sina.com


OBJECTIVE: To explore the role of microRNA-217 in non-small cell lung cancer (NSCLC) and its underlying mechanism.

PATIENTS AND METHODS: MicroRNA-217 expression in 48 NSCLC tissues and paracancerous tissues were detected by qRT-PCR (quantitative Real-time polymerase chain reaction). The relationship between microRNA-217 expression and prognosis of NSCLC patients was analyzed. Target gene of microRNA-217 was predicted by bioinformatics method and further verified by luciferase reporter gene assay. Cell proliferation, cell cycle and apoptosis were detected after altering microRNA-217 expression in NSCLC cells. The effect of microRNA-217 on regulating PI3K pathway was detected by Western blot.

RESULTS: MicroRNA-217 was downregulated in NSCLC tissues than that of paracancerous tissues. Shorter overall survival (OS) was observed in NSCLC patients with lower expression of microRNA-217 than those with higher expression. Overexpressed microRNA-217 remarkably inhibited proliferation and cell cycle, whereas induced apoptosis of NSCLC cells. AKT3 was screened out to be the target gene of microRNA-217. Western blot results demonstrated that microRNA-217 upregulated AKT3 and PI3K pathway-related genes.

CONCLUSIONS: Downregulated microRNA-217 promotes the occurrence and progression of NSCLC through upregulating AKT3 via PI3K pathway.

Free PDF Download

To cite this article

Y.-J. Qi, W.-J. Zha, W. Zhang
MicroRNA-217 alleviates development of non-small cell lung cancer by inhibiting AKT3 via PI3K pathway

Eur Rev Med Pharmacol Sci
Year: 2018
Vol. 22 - N. 18
Pages: 5972-5979
DOI: 10.26355/eurrev_201809_15928